In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Ex-AstraZeneca exec Kristen Buck hops aboard ICON as CMO
Dr. Kristen Buck joins ICON as its new chief medical officer.
-
While the world waits
ICON's Cindy Dukes considers the best practices for developing a vaccine and treatments for COVID-19.
-
ICON nabs former Optum, FDA and AstraZeneca exec as new chief medical officer
Fierce Biotech reports on ICON's appointment of Dr. Kristen Buck as its new chief medical officer.
-
Company of the Month April 2020: ICON plc’s Q1 figures indicate strong growth
Business & Finance names ICON as 'Company of the Month' for April 2020.
-
The U.S. biosimilars market: Shaking the “laggard” label
An article by Katya Svoboda and Bob Swann which explores the fundamental differences in the regulatory processes and the market dynamics of the US and the EU which account for much of the discrepancy in the uptake of biosimilars.
-
DMCs: Maintaining data integrity in COVID-19 climate
A thought leadership article by ICON's Craig McLendon which considers the use of data monitoring committees to support clinical trial management and decision-making during the COVID-19 pandemic.
-
Thwarting Cyber attacks: Steps to implement security into mHealth development
A thought leadership piece authored by David Novotny, Marie McCarthy and Tony Clarke which considers the potential risks of cyber threats in mHealth. See pages 18-19 of the May 2020 edition of PharmaFocus magazine.
-
Coronavirus vaccine: how pharma is picking up the pace
A PharmaPhorum article featuring commentary from ICON's Dr. Nuala Murphy and Dr. James Cummings.
-
COVID-19 will spur decentralised and hybrid trials – Novartis hails digital investment
An article featuring commentary from Dr. Nuala Murphy regarding the use of decentralised and hybrid trials during the COVID-19 crisis.
-
Transforming cell and gene therapy trial design and execution
With over 400 dedicated Cell and Gene Therapy professionals globally, ICON has developed tools and best practices to transform CGT trial design and execution.
